Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)Debora Basile, M. Svrcek, Jaafar Bennouna et al.|Annals of Oncology|2022Cited by 44
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.Alberto F. Sobrero, Qian Shi, Thierry André et al.|Journal of Clinical Oncology|2020Cited by 36
Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.Anthony F. Shields, Timothy Iveson, Fang‐Shu Ou et al.|Journal of Clinical Oncology|2018Cited by 6